58267-85-9

Usage

Uses

Used in Pharmaceutical Industry:
4-BROMOTHIOPHENE-2-CARBOXALDEHYDE ETHYLENE GLYCOL ACETAL is used as an intermediate in the synthesis of various drugs. Its unique structure and reactivity contribute to the development of new pharmaceutical compounds with specific therapeutic properties.
Used in Agrochemical Industry:
In the agrochemical sector, 4-BROMOTHIOPHENE-2-CARBOXALDEHYDE ETHYLENE GLYCOL ACETAL is utilized as a precursor for the production of crop protection agents. Its involvement in the synthesis of these agents helps in creating effective solutions for pest control and crop enhancement.
Used in Material Science:
4-BROMOTHIOPHENE-2-CARBOXALDEHYDE ETHYLENE GLYCOL ACETAL has potential applications in material science, where it can be employed in the development of new materials with tailored properties. Its versatility in chemical reactions allows for the creation of innovative materials for various industries.

InChI:InChI=1/C7H7BrO2S/c8-5-3-6(11-4-5)7-9-1-2-10-7/h3-4,7H,1-2H2

Upstream product

• 18791-75-8 4-Bromothiophen-2-aldehyde 
• 107-21-1 ethylene glycol 

Downstream Products

• 849806-16-2 2-(4-(3-fluoro-phenoxy)-thiophen-2-yl)-[1,3]dioxolane 
• 89324-44-7 3-carboxy-thiophene-5-carboxaldehyde 
• 1309598-08-0 3-(3-bromo-5-[1,3]dioxolan-2-yl-thiophen-2-yl)-benzaldehyde 
• 1309598-09-1 3-(3-bromo-5-[1,3]dioxolan-2-yl-thiophen-2-yl)-benzonitrile 
• 1309598-07-9 [4-(3-bromo-5-[1,3]dioxolan-2-yl-thiophen-2-yl)-phenyl]-acetonitrile 
• 1309598-04-6 4-(3-bromo-5-[1,3]dioxolan-2-yl-thiophen-2-yl)-benzophenone 
• 1305253-05-7 4-(3-bromo-5-[1,3]dioxolan-2-yl-thiophen-2-yl)-benzonitrile 
• 1309598-11-5 2-(3-bromo-5-[1,3]dioxolan-2-yl-thiophen-2-yl)-benzonitrile 
• 1309598-05-7 2-[4-bromo-5-(4-trifluoromethylphenyl)-thiophen-2-yl]-[1,3]dioxolane 
• 1309598-02-4 4-(3-bromo-5-[1,3]dioxolan-2-yl-thiophen-2-yl)-acetophenone 
• 1309598-01-3 4-(3-bromo-5-[1,3]dioxolan-2-yl-thiophen-2-yl)-benzaldehyde 
• 1309598-06-8 2-[4-bromo-5-(4-fluorophenyl)-thiophen-2-yl]-[1,3]dioxolane 
• 1449075-18-6 C₂₀H₁₂Br₂F₈O₄S₂ 

Relevant academic research and scientific papers

Organic small molecular semiconductor material containing anthracene dithiophene as well as preparation method and application thereof

The invention discloses an organic small molecular semiconductor material containing anthracene dithiophene as well as a preparation method and an application thereof. The structural formula of the material is as shown in a formula I, wherein the unit A is an electron deficient group; R1 is hydrogen or alkyl with 1-30 carbon atoms or a group in the alkyl with 1-30 carbon atoms, one or more of which are replaced by halogen atoms, oxygen atoms, alkenyl, alkynyl, aryl, hydroxyl, amino, carboxyl, ester groups, cyan or nitryl. The material has unique advantages of relatively good light capturing ability, proper electronic energy level, relatively high electronic mobility and the like, and is applied to organic solar battery apparatuses as an electron acceptor material to obtain good apparatus performances.

Enantioselective Rhodium-Catalyzed Dimerization of ω-Allenyl Carboxylic Acids: Straightforward Synthesis of C2-Symmetric Macrodiolides

Herein, we report on the first enantioselective and atom-efficient catalytic one-step dimerization method to selectively transform ω-allenyl carboxylic acids into C2-symmetric 14- to 28-membered bismacrolactones (macrodiolides). This convenient asymmetric access serves as an attractive route towards multiple naturally occuring homodimeric macrocyclic scaffolds and demonstrates excellent efficiency to construct the complex, symmetric core structures. By utilizing a rhodium catalyst with a modified chiral cyclopentylidene-diop ligand, the desired diolides were obtained in good to high yields, high diastereoselectivity, and excellent enantioselectivity.

Four and ring kinase inhibitors

The invention belongs to the technical field of medicines and relates to a tetra-cyclo-kinase inhibitor shown in the general formula (I) and its pharmaceutically acceptable salt, stereisomer, ester or solvate. In the general formula (I), R1, R2, R3, R4, M, W, X, Y and Z are defined in the specification. The invention also relates to a preparation method of the compounds, a drug containing the compounds, and a use of the compounds and its pharmaceutically acceptable salt, stereisomer, ester or solvate in preparation of a drug for treating and/or preventing ALK-mediated cancer-related diseases.

Four and circular Anaplastic lymphoma kinase inhibitors

The invention belongs to the technical field of medicine, and more specifically relates to a tetra-heterocyclic-fused anaplastic lymphoma kinase inhibitor represented by general formula (I), and pharmaceutically acceptable salts, stereisomers, esters, or solvates thereof, wherein A1, A2, A3, R1, R2, R3, R4, R5, R6, R7, M, X, and Y are defined by the patent specification. The invention also relates to preparation methods of the compounds above, pharmaceutic preparations and pharmaceutical compositions containing the compounds, and applications of the tetra-heterocyclic-fused anaplastic lymphoma kinase inhibitor, the pharmaceutically acceptable salts, the stereisomers, the esters, or the solvates in preparing medicines used for treating and/or preventing ALK mediated cancer related diseases.

Four and circular Anaplastic lymphoma kinase inhibitors

The invention belongs to the technical field of medicines, and particularly relates to a four-ring anaplastic lymphoma kinase inhibitor as shown in a general formula (I), or stereisomers, or pharmaceutically acceptable salts, esters or solvates of the inhibitor, wherein A1, A2, A3, M, X, Y, Q, R4, R5, R6, R7 and n are defined in the specification. The invention also relates to a preparation method of these compounds, pharmaceutical preparations and pharmaceutical compositions containing these compounds, and application of the compound or the stereisomers, or the pharmaceutically acceptable salts, esters or solvates of the compound in preparation of medicines for treating and/or preventing ALK-mediated cancer related diseases.

NOVEL FUSED HETEROCYCLES AND USES THEREOF

This invention relates to novel compounds having the Formula (I) and to their pharmaceutical compositions and to their methods of use. These novel compounds provide a treatment or prophylaxis of H. pylori infection.

Substituted heteroarylalkanoic acids

Disclosed are substituted heteroarylalkanoic acids acids of the following formula D-A-C(O)R′, where D, A, and R′ are defined herein. These compounds are useful in the treatment of chronic complications arising from diabetes mellitus. Also disclosed are pharmaceutical compositions containing the compounds and methods of treatment employing the compounds, as well as methods for their synthesis.

CONDENSED HETEROCYCLIC COMPOUNDS AS CALCITONIN AGONISTS

The present invention relates to novel fused heterocyclic ring system compounds and methods for their use in the treatment and prevention of diseases or conditions which are related to irregular calcification.

Fused pyridine derivatives

The present provides a condensed pyridine compound (I) represented by the following formula: (wherein, R2represents ring A represents benzene ring, pyridine ring, thiophene ring or furan ring; and B represents its pharmaceutically acceptable salt or hydrates thereof, which is a clinically useful medicament having a serotonin antagonism, in particular, that for treating, ameliorating or preventing spastic paralysis or central muscle relaxants for ameliorating myotonia.